צמיחת הכנסות ב-12 חודשים נגררים: Repligen Corporation (RGEN)

A stable staff of R&D specialists ensures the technological leadership of Repligen Corporation (RGEN). The TTM revenue growth rate compared to the same period last year confirms this trend, where 14.00 serves as the current parameter value. The foundation for growth is built upon the supply of chromatography systems for gene therapy and the implementation of ESG environmental standards in component manufacturing.
פילוחי נתונים אנליטיים מרוכזים עבור Repligen (RGEN)

This indicator measures the daily revenue growth rate over a rolling year, eliminating quarterly reporting gaps to assess demand in real time. An increase in this metric signals business expansion, although it requires accounting for excess capital risks. The rolling year-over-year commercial revenue trend reflects the demand for Repligen Corporation (RGEN) innovative filtration systems. This allows investors to evaluate the effectiveness of the implementation of biopharmaceutical purification technologies.